Vanguard Capital Management
MAIA icon

Vanguard Capital Management’s MAIA Biotechnology MAIA Stock Holding History

Vanguard Capital Management’s Portfolio MAIA Stock Details MAIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.48M Buy
2,413,270
+339,225
+16% +$451K ﹤0.01% 3241
2026
Q1 		$2.9M Buy
+2,074,045
New +$3.82M ﹤0.01% 3244

Other funds holding MAIA

SCM
Solas Capital Management Darien, Connecticut $187M AUM 12.91% 1-Year Est. Return
CWM
Centric Wealth Management Chicago, Illinois $643M AUM 21% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BFG
Bleakley Financial Group Fairfield, New Jersey $7.85B AUM 31.48% 1-Year Est. Return

Vanguard Capital Management's MAIA Position: Q2 2026 in Review

Vanguard Capital Management increased its MAIA Biotechnology (MAIA) stake by 16% in Q2 2026, buying an estimated $451K and bringing the position to 2,413,270 shares worth $3.48M. The position accounts for ﹤0.01% of the portfolio, ranked #3241.

Vanguard Capital Management first reported a position in MAIA in Q1 2026 and has held it in 2 quarters since. 35 funds tracked by Wall St. Rank hold MAIA as of Q2 2026.

  • Vanguard Capital Management held 2,413,270 shares of MAIA Biotechnology worth $3.48M as of Q2 2026.
  • Vanguard Capital Management bought 339,225 MAIA Biotechnology shares in Q2 2026, an estimated $451K.
  • MAIA Biotechnology made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3241 holding.
  • Vanguard Capital Management first reported a position in MAIA Biotechnology in Q1 2026 and has held it in 2 quarters since.
  • 35 funds tracked by Wall St. Rank held MAIA Biotechnology as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.